Guidance Document: Tamper-resistance Formulations of Opioid Drug Products (English, HTML)

View metadata and access the original English HTML file: Guidance Document: Tamper-resistance Formulations of Opioid Drug Products.

Format

HTML

Access

file-only

Publisher-reported update

2021-07-07

This guidance document is specific to the "tamper-resistance" feature of controlled-release opioid products. It is intended for the pre-market review of drug submissions when sponsors seek to obtain approval for controlled-release opioid drug formulations with tamper-resistant properties and wish to include, in product monographs, scientific statements and claims regarding tamper-resistance.

Access original file